Fmr LLC Boosts Stake in IQVIA Holdings Inc. (NYSE:IQV)

FMR LLC lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 38.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,887,342 shares of the medical research company's stock after buying an additional 804,963 shares during the quarter. FMR LLC owned about 1.59% of IQVIA worth $684,213,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. PGGM Investments grew its position in shares of IQVIA by 55.8% during the second quarter. PGGM Investments now owns 12,073 shares of the medical research company's stock worth $2,553,000 after acquiring an additional 4,326 shares during the last quarter. Simplify Asset Management Inc. raised its holdings in shares of IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock valued at $2,284,000 after buying an additional 3,894 shares during the last quarter. Raymond James & Associates grew its holdings in shares of IQVIA by 0.7% during the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company's stock worth $169,231,000 after buying an additional 5,417 shares during the last quarter. Versor Investments LP acquired a new position in IQVIA in the 3rd quarter valued at about $1,328,000. Finally, Gradient Investments LLC raised its stake in IQVIA by 15.6% during the 2nd quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company's stock valued at $9,600,000 after acquiring an additional 6,134 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on IQV shares. Robert W. Baird dropped their target price on IQVIA from $256.00 to $223.00 and set a "neutral" rating on the stock in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. Leerink Partners restated an "outperform" rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, JPMorgan Chase & Co. lowered their target price on IQVIA from $279.00 to $240.00 and set an "overweight" rating on the stock in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $256.50.

IQVIA Stock Down 0.3 %

Shares of NYSE IQV traded down $0.59 on Friday, hitting $200.84. The company had a trading volume of 513,713 shares, compared to its average volume of 1,174,636. The firm has a market capitalization of $36.45 billion, a P/E ratio of 26.43, a PEG ratio of 2.07 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The business has a 50 day moving average of $219.50 and a two-hundred day moving average of $226.40.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.